Vytorin outcomes data will be a year late, Merck says; Forest promos cited after doc tattled;

 @FiercePharma: HBR has an interesting piece by Pfizer's Susan Silbermann, on sales strategies in Latin America. More | Follow @FiercePharma

> Merck ($MRK) said key outcomes data on its cholesterol drug Zetia, part of the combo treatment Vytorin, would be available in 2014, a year later than anticipated. Report

> Ranbaxy Laboratories posted a surprise loss of $106 million (5.68 billion rupees) as the currency lost value, despite North American sales that more than doubled. Report

> Forest Laboratories was cited by the FDA's advertising police after doctors reported misstatements by company sales reps about its drug Daliresp. Report

> ViroPharma ($VPHM) now expects Cinryze sales to surpass previous estimates for the year, to $320 million to $335 million. Report

> Novartis' ($NVS) Alcon unit won an appeals court ruling that backed its eye drug Patanol till 2015, barring Apotex from launching a generic version. Report

> Medicis Pharma slashed its earnings and revenue guidance after second-quarter profits fell. Report

> The Federal Trade Commission determined that the Generic Pharmaceutical Association's drug-shortage initiative with the FDA wouldn't interfere with industry competition. Release

> Philippines President Benigno Aquino warned an unidentified drugmaker against a 750% increase in price for a leptospirosis drug, in anticipation of an outbreak because of recent flooding. Report

Medical Device News

@FierceMedDev: China's medical imaging market should exceed $2.5 billion by 2016, a new analysis concludes. Release | Follow @FierceMedDev

 @MarkHFierce: Given Imaging experienced a mixed Q2. Meanwhile, the company is winding up for two regulatory submissions. More | Follow @MarkHFierce

 @DamianFierce: In Q2, Alere's big revenue boost was negated by charges and costs related to its Dx recall. More  | Follow @DamianFierce

> Exact Sciences seeks $50.2M in public offering. Story

> Former Home Diagnostics chief pleads guilty to insider trading. Report

> FDA dramatically limits use of Stryker's Wingspan brain stent. More

Biotech News

 @FierceBiotech: Pfizer taps biotech startup to tailor R&D of lupus, autoimmune drugs More | Follow @FierceBiotech

 @JohnCFierce: Old pharma guys never die. They just go into venture capital. Now it's Jeff Kindler's turn. More | Follow @JohnCFierce

 @RyanMFierce: Buzz on the street: Who thinks Icahn can succeed in biotech without two aces, Denner and Mulligan? More | Follow @RyanMFierce

> Pfizer taps biotech startup to tailor R&D of lupus, autoimmune drugs. Article

> Amgen ditches PhIII effort for drug against pancreatic cancer. News

> Cancer stem cells prove tough IPO sell for Stemline. Article

> Merck hits the brakes on combo cholesterol drug. Story

Vaccines News

> Sanofi readies defense as judge rules antitrust lawsuit can proceed. Story

> Tuberculosis vaccine may reverse Type 1 diabetes. Item

> Immatics' kidney cancer vaccine extends lives in trials. News

> Researchers discover malaria target. Article

> FDA lifts hold on Allergy Therapeutics' grass pollen allergy vax. Story

> CDC preps for emerging swine flu strain. More

Pharma Manufacturing News

> FDA tells drugmaker quality can't be added after production. More

> Chinese firm nailed with import alert over unsanitary plant. News

> Amgen to idle Epogen plant as sales fade away. Story

And Finally... New targeted cancer therapies appear to trigger fewer side effects than older drugs, a study found. Report